Trials / Completed
CompletedNCT03681379
Pharmacokinetics of Levosimendan in Pediatric Intensive Care Units
Pharmacokinetics of Levosimendan, OR1855 and OR1896 in Neonates and Children With or Without Extracorporeal Membrane Oxygenation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 27 (actual)
- Sponsor
- Nantes University Hospital · Academic / Other
- Sex
- All
- Age
- 0 Days – 18 Years
- Healthy volunteers
- Not accepted
Summary
To describe pharmacokinetics of levosimendan in neonates and children supported or not with extracorporeal circulation devices (ECMO, CRRT)
Detailed description
Levosimendan is a calcium sensitiver wih inotropic effects. It's use in the context of acute or chronic heart failure in children has yet to be defined. Due to physical proprieties of levosimendan and metabolites, we hypothesized that concomitant use of extracorporeal devices such as ECMO will cause major pharmacokinetic variations. Furthermore, pharmacokinetics of levosimendan in children with multiple organ failure has to be specify.
Conditions
Timeline
- Start date
- 2018-09-23
- Primary completion
- 2019-10-11
- Completion
- 2020-10-01
- First posted
- 2018-09-24
- Last updated
- 2024-08-02
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03681379. Inclusion in this directory is not an endorsement.